To assess and compare the effectiveness and safety of olopatadine 0.7 percent and alcatadine 0.25 percent in patients with allergic conjunctivitis.
- Conditions
- Health Condition 1: H108- Other conjunctivitis
- Registration Number
- CTRI/2024/05/067217
- Lead Sponsor
- Pt B.D. Sharma UHS Rohtak
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Positive medical history of mild to moderate ocular allergies.
-Best corrected visual acuity of 6 by 12 or better in each eye.
-Absence of contact lens use for a minimum of three days before and throughout the study period.
-Willingness to provide informed consent
-Diagnosis of persistent dry eye syndrome.
-Use of any topical eye drops, including ocular lubricants, aside from the investigational drugs within the past seventy two hours, or utilization of any experimental medications or devices within the last thirty days.
-Taking aspirin, or related products, systemic steroids or H1antihistamines within seven days prior to enrolment.
-Presence of an active ocular infection.
-Planned surgical procedures during the study period or recent ocular surgical intervention within three months.
-Pregnancy and lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method